| Autor: |
Schlam I; Tufts Medical Center, Division of Hematology and Oncology, Boston, Massachusetts, USA., Ewer MS; MD Anderson Cancer Center, Houston, Texas, USA., Swain SM; Georgetown Lombardi Comprehensive Cancer Center and MedStar Health, Washington, DC, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
JACC. CardioOncology [JACC CardioOncol] 2023 Feb 21; Vol. 5 (1), pp. 99-101. Date of Electronic Publication: 2023 Feb 21 (Print Publication: 2023). |
| DOI: |
10.1016/j.jaccao.2022.12.003 |
| Abstrakt: |
Competing Interests: Dr Swain is a member of the independent data monitoring committee for AstraZeneca; is a consultant for Athenex, Daiichi-Sankyo, Silverback Therapeutics, Molecular Therapeutics, Exact Sciences (Genomic Health), Beijing Medical Foundation, Natera, AstraZeneca, Genentech/Roche, Merck, Lilly, Biotheranostics, and Aventis; has received travel costs from Daichi Sankyo and Aventis; has done nonpromotional speaking for Genentech/Roche; has performed research for Genentech/Roche and Kailos Genetics; has provided third-party writing assistance to Genentech/Roche, AstraZeneca; and is on the Seagen Board of Directors. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
